Medicis Pharmaceutical Corporation: Premium Company Profile

Questions: Discounts, Updates etc.

Price: $495.00

Publication Date: 2007-12-24

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Medicis Pharmaceutical focuses on the development and marketing products for the treatment of dermatological, aesthetic and podiatric conditions in the US. It has branded prescription products in a number of therapeutic categories, including acne, fungal infections, psoriasis, rosacea, seborrheic dermatitis, and skin and skin-structure infections.


Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


    • Report Highlights
    The company is involved in developing and marketing dermatological and aesthetics products. Its current products are divided between the dermatological and non-dermatological fields. In the dermatological field it offers products such as Dynacin, Plexion, Solodyn, Triaz and Ziana for the treatment of acne and acne-related dermatological conditions

    Medicis generates its revenues from product sales and contracts. The company's total revenues increased at a CAGR of 13% during 2002-2006, from $213 million to $349 million. This represents an absolute growth of +$126 million during the historical period. Product sales were the largest contributor to the total revenue growth.

    Medicis' biggest contributor to sales growth out to 2010 will be the product sales (excluding Reloxin) and contract and licensing revenues. Revenues from these streams together are expected to contribute the entire +$368 million of absolute growth during the period 2006-2010.


    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company's adjusted five year financial data along with key ratios and market capitalization

    • Table of Contents

    Other users found this report page using the following search terms: medicis pharmaceutical pharmaceuticals ziana joseph cooper restylane clinical revenue swot

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.